Year: 2012
Type: article
Abstract: Reduction of active disease by preventive therapy has the potential to make an important contribution towards the goal of tuberculosis (TB) elimination. This report summarises discussions amongst a Working Group convened to consider areas of research that will be important in optimising the design and delivery of preventative therapies. The Working Group met in Cape Town on 26th February 2012, following presentation of results from the GC11 Grand Challenges in Global Health project to discover drugs for latent TB.
Source: Tuberculosis
Authors: Brian D. Robertson, Danny Altmann, Clif Barry, Bill Bishai, Stewart Cole, Thomas Dick, Ken Duncan, Chris Dye, Sabine Ehrt, Hanif Esmail, JoAnne Flynn, Richard Hafner, Gray Handley, Willem Hanekom, Paul van Helden, Gilla Kaplan, Stefan H.E. Kaufmann, Peter Kim, Christian Lienhardt, Valerie Mizrahi, Eric Rubin, Dirk Schnappinger, David Sherman, Jelle Thole, Omar Vandal, Gerhard Walzl, Digby Warner, Robert Wilkinson, Douglas Young
Institutions: Imperial College London, Wellcome Trust, National Institutes of Health, National Institute of Allergy and Infectious Diseases, University of KwaZulu-Natal, École Polytechnique Fédérale de Lausanne, National University of Singapore, Gates Foundation, World Health Organization, Weill Cornell Medicine, University of Pittsburgh, University of Cape Town, Stellenbosch University, Max Planck Society, Max Planck Institute for Infection Biology, Harvard University, Center for Infectious Disease Research, TuBerculosis Vaccine Initiative, Medical Research Council
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,690
OpenAlex ID: W2071074290